BML, Inc. (4694) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

62.3 k

Shareholding (Mar 2022)

FII

0.05%

Held by 1 FIIs

DII

99.95%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROE of 13.86%

Company has very low debt and has enough cash to service the debt requirements

With ROE of 5.04%, it has a very attractive valuation with a 0.99 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 156,066 Million (Small Cap)

P/E

20.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.51

Return on Equity

5.19%

Price to Book

1.21

Revenue and Profits:

Net Sales:

38,026 Million

(Quarterly Results - Jun 2025)

Net Profit:

1,932 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

2.55%

6 Months

19.19%

1 Year

31.05%

2 Years

32.64%

3 Years

13.69%

4 Years

6.11%

5 Years

11.86%

BML, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

BML, Inc. Adjusts Valuation Amidst Financial Landscape Challenges and Performance Metrics

BML, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment. This change highlights the company's valuation metrics, including its P/E ratio, Price to Book Value, and operational efficiency indicators, reflecting its financial health and market position amidst recent performance challenges.

BML, Inc. Shows Strong Financial Metrics Amid Evolving Market Position

BML, Inc., a small-cap pharmaceutical company, has recently adjusted its evaluation, reflecting its competitive market position. With strong financial metrics, including a notable P/E ratio and low debt levels, the company has outperformed the broader market over the past year, showcasing solid operational efficiency and management effectiveness.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.47%

EBIT Growth (5y)

-0.83%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.51

Sales to Capital Employed (avg)

1.14

Tax Ratio

32.71%

Dividend Payout Ratio

74.72%

Pledged Shares

Institutional Holding

0.05%

ROCE (avg)

70.82%

ROE (avg)

13.86%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.99

EV to EBIT

6.69

EV to EBITDA

3.67

EV to Capital Employed

0.99

EV to Sales

0.44

PEG Ratio

4.95

Dividend Yield

ROCE (Latest)

14.76%

ROE (Latest)

5.04%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2022

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 9.86% vs -6.97% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 83.82% vs -44.71% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "38,026.00",
          "val2": "34,612.00",
          "chgp": "9.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,947.00",
          "val2": "3,566.00",
          "chgp": "38.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "30.00",
          "val2": "30.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-10.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,932.00",
          "val2": "1,051.00",
          "chgp": "83.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "73.80%",
          "val2": "35.30%",
          "chgp": "3.85%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 3.79% vs -13.48% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 3.93% vs -61.23% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "143,191.00",
          "val2": "137,964.00",
          "chgp": "3.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "17,081.00",
          "val2": "15,959.00",
          "chgp": "7.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "118.00",
          "val2": "104.00",
          "chgp": "13.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.00",
          "val2": "-5.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,509.00",
          "val2": "6,263.00",
          "chgp": "3.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "65.40%",
          "val2": "66.50%",
          "chgp": "-0.11%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

38,026.00

34,612.00

9.86%

Operating Profit (PBDIT) excl Other Income

4,947.00

3,566.00

38.73%

Interest

30.00

Exceptional Items

0.00

-10.00

100.00%

Consolidate Net Profit

1,932.00

1,051.00

83.82%

Operating Profit Margin (Excl OI)

73.80%

35.30%

3.85%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 9.86% vs -6.97% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 83.82% vs -44.71% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

143,191.00

137,964.00

3.79%

Operating Profit (PBDIT) excl Other Income

17,081.00

15,959.00

7.03%

Interest

118.00

104.00

13.46%

Exceptional Items

-10.00

-5.00

-100.00%

Consolidate Net Profit

6,509.00

6,263.00

3.93%

Operating Profit Margin (Excl OI)

65.40%

66.50%

-0.11%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 3.79% vs -13.48% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 3.93% vs -61.23% in Mar 2024

All Annual Results

Company CV

About BML, Inc.

BML, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

BML, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

High Management Efficiency with a high ROE of 13.86%

Company has very low debt and has enough cash to service the debt requirements

With ROE of 5.04%, it has a very attractive valuation with a 0.99 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

BML, Inc. Adjusts Valuation Amidst Financial Landscape Challenges and Performance Metrics

BML, Inc. Shows Strong Financial Metrics Amid Evolving Market Position

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2022

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Mar'25

About BML, Inc.

Company Coordinates